Roth Capital Initiates Coverage On Newly Listed Unicycive
Roth Capital initiated coverage of Unicycive Therapeutics (NASDAQ:UNCY) with a Buy rating and $13.50 price target. Analyst Elemer Piros says that the Company could submit…
Roth Capital Initiates Coverage On Unicycive Therapeutics with Buy Rating, Announces Price Target of $13.5
Roth Capital analyst Elemer Piros initiates coverage on Unicycive Therapeutics (NASDAQ:UNCY) with a Buy rating and announces Price Target of $13.5.
The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 5)
Stocks That Hit 52-Week Lows On Thursday
During Thursday's morning session, 77 companies made new 52-week lows.
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies.
75 Biggest Movers From Friday
Gainers
The New Home Company Inc. (NYSE: NWHM) jumped 82.9% to settle at $8.89 on Friday after the company agreed to be acquired by funds managed by affiliates of Apollo Global Management for $9 per share in all-cash transaction.